Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded at HC Wainwright

Sensei Biotherapeutics (NASDAQ:SNSE) was upgraded by investment analysts at HC Wainwright to a “buy” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage presently has a $5.00 price target on the stock.

A number of other research firms have also recently weighed in on SNSE. Oppenheimer upped their price target on Sensei Biotherapeutics from $3.50 to $4.00 and gave the stock an “outperform” rating in a report on Friday, March 28th. Stephens upgraded Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, May 1st.

Sensei Biotherapeutics Trading Up 4.5%

Shares of Sensei Biotherapeutics stock opened at $0.32 on Monday. Sensei Biotherapeutics has a twelve month low of $0.25 and a twelve month high of $0.87. The stock has a market capitalization of $7.95 million, a P/E ratio of -0.26 and a beta of 0.19. The business’s fifty day moving average price is $0.36 and its 200 day moving average price is $0.44.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.06). As a group, sell-side analysts predict that Sensei Biotherapeutics will post -1.17 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. XTX Topco Ltd boosted its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,903 shares of the company’s stock after buying an additional 48,977 shares during the quarter. XTX Topco Ltd owned 0.25% of Sensei Biotherapeutics worth $31,000 at the end of the most recent quarter. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.